BriaCell Therapeutics Corp. SEC filings BCTXZ
BriaCell Therapeutics Corp. has 324 filings in SEC EDGAR's recent list, going back to Jun 20, 2014. Its latest annual report, Form 10-K, was filed on Oct 28, 2026 for the period ended Jul 31, 2026. The latest quarterly report (Form 10-Q) was filed on Jun 9, 2026, covering the quarter ended Apr 30, 2026. The most recent current report (Form 8-K) was filed on Jun 26, 2026 (regulation fd disclosure). The company's fiscal year ends on July 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure
|
Jun 26, 2026 | Jun 26, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Other events
|
Jun 3, 2026 | May 31, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Mar 31, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Mar 9, 2026 | Mar 5, 2026 |
| 8-K |
Current report
Other events
|
Feb 20, 2026 | Feb 18, 2026 |
| 8-K |
Current report
Material agreement, Other events
|
Jan 15, 2026 | Jan 13, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Dec 29, 2025 | Dec 29, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Dec 1, 2025 | Nov 28, 2025 |
| 8-K |
Current report
Other events
|
Aug 26, 2025 | Aug 21, 2025 |
| 8-K |
Current report
Material agreement, Other events
|
Jul 16, 2025 | Jul 15, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 18, 2025 | Jun 16, 2025 |
| 8-K |
Current report
Material agreement, Other events
|
Apr 28, 2025 | Apr 24, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Mar 12, 2025 | Mar 12, 2025 |
| 8-K |
Current report
Other events
|
Feb 13, 2025 | Feb 12, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Feb 6, 2025 | Feb 5, 2025 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Other events
|
Feb 5, 2025 | Feb 3, 2025 |
| 8-K |
Current report
Other events
|
Jan 28, 2025 | Jan 24, 2025 |
| 8-K |
Current report
Other events
|
Jan 3, 2025 | Jan 3, 2025 |
| 8-K |
Current report
Other events
|
Jan 3, 2025 | Jan 3, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Dec 16, 2024 | Dec 12, 2024 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Other events
|
Dec 13, 2024 | Dec 11, 2024 |
| 8-K |
Current report
Officer or director change
|
Nov 25, 2024 | Nov 23, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Nov 1, 2024 | Nov 1, 2024 |
| 8-K |
Current report
Material agreement, Other events
|
Oct 2, 2024 | Oct 1, 2024 |
| 8-K |
Current report
Other events
|
Oct 1, 2024 | Oct 1, 2024 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Other events
|
Sep 12, 2024 | Sep 11, 2024 |
| 8-K |
Current report
Other events
|
Sep 11, 2024 | Sep 9, 2024 |
| 8-K |
Current report
Listing notice
|
Aug 23, 2024 | Aug 22, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Jul 18, 2024 | Jul 18, 2024 |
| 8-K |
Current report
Listing notice
|
Jul 5, 2024 | Jul 3, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 14, 2024 | Jun 14, 2024 |
| 8-K |
Current report
Material agreement, Other events
|
May 17, 2024 | May 14, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Apr 2, 2024 | Apr 1, 2024 |
| 8-K |
Current report
Shareholder vote results
|
Jan 31, 2024 | Jan 30, 2024 |
| 8-K |
Current report
Other events
|
Dec 20, 2023 | Dec 20, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Dec 14, 2023 | Dec 14, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Nov 30, 2023 | Nov 30, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Nov 3, 2023 | Nov 3, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 25, 2023 | Oct 25, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 8, 2023 | Sep 8, 2023 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Sep 7, 2023 | Aug 31, 2023 |
| 8-K |
Current report
Other events
|
Aug 31, 2023 | Aug 31, 2023 |
| 8-K |
Current report
Other events
|
Aug 31, 2023 | Aug 31, 2023 |
| 8-K |
Current report
Other events
|
Aug 25, 2023 | Aug 25, 2023 |
| 8-K |
Current report
Shareholder vote results, Other events
|
Aug 21, 2023 | Aug 18, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 27, 2023 | Jun 27, 2023 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
May 31, 2023 | May 24, 2023 |
| 8-K |
Current report
Unregistered share sale
|
May 22, 2023 | May 19, 2023 |
| 8-K |
Current report
Material agreement
|
May 15, 2023 | May 9, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Apr 17, 2023 | Apr 17, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Mar 30, 2023 | Mar 30, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Feb 23, 2023 | Feb 23, 2023 |
| 8-K |
Current report
Bylaw or fiscal year change, Shareholder vote results
|
Feb 15, 2023 | Feb 9, 2023 |
| 8-K |
Current report
Other events
|
Feb 10, 2023 | Feb 9, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Jan 24, 2023 | Jan 24, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Jan 23, 2023 | Jan 23, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Jan 18, 2023 | Jan 18, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Jan 10, 2023 | Jan 10, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Dec 8, 2022 | Dec 8, 2022 |
| 8-K |
Current report
Regulation FD disclosure
|
Nov 30, 2022 | Nov 30, 2022 |
| 8-K |
Current report
Regulation FD disclosure
|
Nov 10, 2022 | Nov 10, 2022 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure, Other events
|
Oct 28, 2022 | Oct 27, 2022 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 21, 2022 | Oct 21, 2022 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 14, 2022 | Sep 14, 2022 |
| 8-K |
Current report
Material agreement
|
Aug 4, 2022 | Aug 1, 2022 |
| 6-K | Current report (foreign issuer) | Jul 18, 2022 | Jul 18, 2022 |
| 6-K | Current report (foreign issuer) | Jul 5, 2022 | Jul 5, 2022 |
| 6-K | Current report (foreign issuer) | Jun 29, 2022 | Jun 29, 2022 |
| 6-K | Current report (foreign issuer) | Jun 24, 2022 | Jun 24, 2022 |
| 6-K | Current report (foreign issuer) | Jun 13, 2022 | Apr 30, 2022 |
| 6-K | Current report (foreign issuer) | May 18, 2022 | May 18, 2022 |
| 6-K | Current report (foreign issuer) | Apr 13, 2022 | Apr 13, 2022 |
| 6-K | Current report (foreign issuer) | Apr 12, 2022 | Apr 12, 2022 |
| 6-K | Current report (foreign issuer) | Apr 7, 2022 | Apr 7, 2022 |
| 6-K | Current report (foreign issuer) | Mar 15, 2022 | Jan 31, 2022 |
| 6-K | Current report (foreign issuer) | Feb 28, 2022 | Feb 28, 2022 |
| 6-K | Current report (foreign issuer) | Feb 23, 2022 | Feb 23, 2022 |
| 6-K | Current report (foreign issuer) | Feb 16, 2022 | Feb 16, 2022 |
| 6-K | Current report (foreign issuer) | Feb 10, 2022 | Feb 10, 2022 |
| 6-K | Current report (foreign issuer) | Jan 20, 2022 | Jan 20, 2022 |
| 6-K | Current report (foreign issuer) | Jan 5, 2022 | Jan 4, 2022 |
| 6-K | Current report (foreign issuer) | Dec 30, 2021 | Dec 30, 2021 |
| 6-K | Current report (foreign issuer) | Dec 17, 2021 | Dec 16, 2021 |
| 6-K | Current report (foreign issuer) | Dec 15, 2021 | Dec 15, 2021 |
| 6-K | Current report (foreign issuer) | Dec 9, 2021 | Dec 9, 2021 |
| 6-K | Current report (foreign issuer) | Nov 19, 2021 | Nov 18, 2021 |
| 6-K | Current report (foreign issuer) | Nov 12, 2021 | Nov 12, 2021 |
| 6-K | Current report (foreign issuer) | Nov 5, 2021 | Nov 5, 2021 |
| 6-K | Current report (foreign issuer) | Nov 2, 2021 | Nov 2, 2021 |
| 6-K | Current report (foreign issuer) | Oct 29, 2021 | Oct 29, 2021 |
| 6-K | Current report (foreign issuer) | Oct 5, 2021 | Oct 5, 2021 |
| 6-K | Current report (foreign issuer) | Sep 22, 2021 | Sep 22, 2021 |
| 6-K | Current report (foreign issuer) | Sep 9, 2021 | Sep 9, 2021 |
| 6-K | Current report (foreign issuer) | Sep 1, 2021 | Sep 1, 2021 |
| 6-K | Current report (foreign issuer) | Aug 23, 2021 | Aug 23, 2021 |
| 6-K | Current report (foreign issuer) | Aug 19, 2021 | Aug 19, 2021 |
| 6-K | Current report (foreign issuer) | Aug 17, 2021 | Aug 17, 2021 |
| 6-K | Current report (foreign issuer) | Aug 13, 2021 | Aug 12, 2021 |
| 6-K | Current report (foreign issuer) | Jul 14, 2021 | Jul 14, 2021 |
| 6-K | Current report (foreign issuer) | Jul 12, 2021 | Jul 12, 2021 |
| 6-K | Current report (foreign issuer) | Jul 8, 2021 | Jul 8, 2021 |
| 6-K | Current report (foreign issuer) | Jun 30, 2021 | Jun 30, 2021 |
| 6-K | Current report (foreign issuer) | Jun 16, 2021 | Jun 16, 2021 |
| 6-K | Current report (foreign issuer) | Jun 10, 2021 | Jun 10, 2021 |
| 6-K | Current report (foreign issuer) | Jun 9, 2021 | Jun 9, 2021 |
| 6-K | Current report (foreign issuer) | Jun 8, 2021 | Jun 8, 2021 |
| 6-K | Current report (foreign issuer) | Jun 4, 2021 | Jun 4, 2021 |
| 6-K | Current report (foreign issuer) | Jun 2, 2021 | Jun 2, 2021 |
| 6-K | Current report (foreign issuer) | May 20, 2021 | May 19, 2021 |
| 6-K | Current report (foreign issuer) | May 11, 2021 | May 11, 2021 |
| 6-K | Current report (foreign issuer) | Apr 27, 2021 | Apr 27, 2021 |
| 6-K | Current report (foreign issuer) | Apr 16, 2021 | Apr 16, 2021 |
| 6-K | Current report (foreign issuer) | Apr 12, 2021 | Apr 12, 2021 |
| 6-K | Current report (foreign issuer) | Apr 1, 2021 | Apr 1, 2021 |
| 6-K | Current report (foreign issuer) | Mar 31, 2021 | Mar 31, 2021 |
| 6-K | Current report (foreign issuer) | Mar 2, 2021 | Mar 1, 2021 |
Showing 116 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- BCTX (Nasdaq), BCTXL (Nasdaq), BCTXZ (Nasdaq)
- Fiscal year ends
- July 31
- Incorporated in
- British Columbia, Canada
- Headquarters
- West Vancouver, British Columbia, Canada
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1610820
- Former names
- Ansell Capital Corp. (until Jun 20, 2014)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.